HighField Bio
  • Home
  • Oncology
    • Oncology Pipeline
    • ADCplex™ Platform – K1
    • TCEplex™ T cell Engager – HF50
    • Immune Modulator – K16
  • Gene Therapy
    • Gene Therapy Pipeline
    • HFG1
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文
HighField Bio
  • Home
  • Oncology
    • Oncology Pipeline
    • ADCplex™ Platform – K1
    • TCEplex™ T cell Engager – HF50
    • Immune Modulator – K16
  • Gene Therapy
    • Gene Therapy Pipeline
    • HFG1
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文

Search Posts

About Us

Lorem ipsum dolor sit amet, consectetur adipisc
glelit, sed do eiusmod tempor incididunt .ut labo
et dolore magna aliqua.

Blog Categories

  • HighField in the News (4)
  • Press Release (17)
  • Publications (17)
  • References (21)
  • Uncategorized (6)

Recent Posts

Post placeholder image
July 16, 2025

HighField Biopharmaceuticals Dosed First Patient in Phase 1 Trial of Liposomal T Cell Engager HF50 (TCEplex)

by PJWCreative
Post placeholder image
May 28, 2025

ASCO 2025 Abstract: First in human PK analysis of antibody conjugated liposome encapsulating doxorubicin (HF-K1) in advanced cancer patients: Comparison with ADCs.

by PJWCreative
Post placeholder image
April 30, 2025

AACR 2025 Poster: Myeloid cell targeted immune modulation in solid tumor and brain tumor patients: an analysis of NCTO5388487 phase 1 study data.

by PJWCreative
April 21, 2025

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs

by HighField Bio
April 7, 2025

HighField Biopharmaceuticals’ Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting

by PJWCreative
January 13, 2025

Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases

by PJWCreative

Recent Comments

No comments to show.

Tags

General HF50 HFG1 K1 K16

Post placeholder image
August 30, 2022 in References

Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
July 17, 2022 in References

Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer

PJWCreative 0 Like Post Comments Off on Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer
Read More
Post placeholder image
December 28, 2016 in References

Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors

PJWCreative 0 Like Post 0 Comment
Read More

Download Company Profile

Home
Technology
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

Linkedin Weixin
HIGHfield_logo_horizontal_FINAL_trans

Home
Technology
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

HIGHFIELD_web_LI_icon_x75

© 2024 HighField Biopharmaceuticals, Inc.   Terms of Use.       
LipoADCplex™ and TRAFsome™ are trademarks of HighField Biopharmaceuticals, Inc

en_US English
en_US English
zh_CN 简体中文